Cargando…

Ecopharmacovigilance: Current state, challenges, and opportunities in China

In a context of severe pharmaceutical pollution, “ecopharmacovigilance” (EPV) has been an area of novel interest. It aims to ensure that significant environmental issues associated with pharmaceuticals in the environment are identified in a timely way, and managed appropriately. EPV has become a res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Hu, Xiamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912800/
https://www.ncbi.nlm.nih.gov/pubmed/24550578
http://dx.doi.org/10.4103/0253-7613.125158
_version_ 1782302137952239616
author Wang, Jun
Hu, Xiamin
author_facet Wang, Jun
Hu, Xiamin
author_sort Wang, Jun
collection PubMed
description In a context of severe pharmaceutical pollution, “ecopharmacovigilance” (EPV) has been an area of novel interest. It aims to ensure that significant environmental issues associated with pharmaceuticals in the environment are identified in a timely way, and managed appropriately. EPV has become a research hotspot as a comprehensive and boundary science in Europe and North America, and regulatory requirements governing the comprehensive environmental risk assessment (ERA) of pharmaceuticals exist in these regions. A speedy Chinese pharmaceutical industry development and drug consumption, China should shoulder more international responsibility and contribute to the worldwide EPV. Compared to the west, EPV in China is in its infancy. We analyzed the current state of EPV-related practice in China and found that many efforts have been made by the Chinese government and specialists to control the ever-worsening environmental pharmaceutical pollution problems, including consummating related policies and regulations, revealing the occurrence and behavior of pharmaceutical residues in environment and developing new technologies to improve their removal performance. Besides, we posed some recommendations on appropriate EPV implementation that can be taken with China in future. These include, building perfect laws and regulation system on EPV, defining the evaluation index for EPV, continuing the clinical rational medication and the pharmaceutical take-back programs in China, popularizing the concept of EPV in China, and strengthening the policy-guided and scientific researches of EPV in pharmaceutical firms and academia.
format Online
Article
Text
id pubmed-3912800
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39128002014-02-18 Ecopharmacovigilance: Current state, challenges, and opportunities in China Wang, Jun Hu, Xiamin Indian J Pharmacol Research Article In a context of severe pharmaceutical pollution, “ecopharmacovigilance” (EPV) has been an area of novel interest. It aims to ensure that significant environmental issues associated with pharmaceuticals in the environment are identified in a timely way, and managed appropriately. EPV has become a research hotspot as a comprehensive and boundary science in Europe and North America, and regulatory requirements governing the comprehensive environmental risk assessment (ERA) of pharmaceuticals exist in these regions. A speedy Chinese pharmaceutical industry development and drug consumption, China should shoulder more international responsibility and contribute to the worldwide EPV. Compared to the west, EPV in China is in its infancy. We analyzed the current state of EPV-related practice in China and found that many efforts have been made by the Chinese government and specialists to control the ever-worsening environmental pharmaceutical pollution problems, including consummating related policies and regulations, revealing the occurrence and behavior of pharmaceutical residues in environment and developing new technologies to improve their removal performance. Besides, we posed some recommendations on appropriate EPV implementation that can be taken with China in future. These include, building perfect laws and regulation system on EPV, defining the evaluation index for EPV, continuing the clinical rational medication and the pharmaceutical take-back programs in China, popularizing the concept of EPV in China, and strengthening the policy-guided and scientific researches of EPV in pharmaceutical firms and academia. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC3912800/ /pubmed/24550578 http://dx.doi.org/10.4103/0253-7613.125158 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Jun
Hu, Xiamin
Ecopharmacovigilance: Current state, challenges, and opportunities in China
title Ecopharmacovigilance: Current state, challenges, and opportunities in China
title_full Ecopharmacovigilance: Current state, challenges, and opportunities in China
title_fullStr Ecopharmacovigilance: Current state, challenges, and opportunities in China
title_full_unstemmed Ecopharmacovigilance: Current state, challenges, and opportunities in China
title_short Ecopharmacovigilance: Current state, challenges, and opportunities in China
title_sort ecopharmacovigilance: current state, challenges, and opportunities in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912800/
https://www.ncbi.nlm.nih.gov/pubmed/24550578
http://dx.doi.org/10.4103/0253-7613.125158
work_keys_str_mv AT wangjun ecopharmacovigilancecurrentstatechallengesandopportunitiesinchina
AT huxiamin ecopharmacovigilancecurrentstatechallengesandopportunitiesinchina